675 related articles for article (PubMed ID: 30877063)
41. Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations?
Lucas MC; Tan SL
Future Med Chem; 2014; 6(16):1811-27. PubMed ID: 25407369
[TBL] [Abstract][Full Text] [Related]
42. Kinase targets in CNS drug discovery.
Gunosewoyo H; Yu L; Munoz L; Kassiou M
Future Med Chem; 2017 Mar; 9(3):303-314. PubMed ID: 28176536
[TBL] [Abstract][Full Text] [Related]
43. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
Wu P; Nielsen TE; Clausen MH
Drug Discov Today; 2016 Jan; 21(1):5-10. PubMed ID: 26210956
[TBL] [Abstract][Full Text] [Related]
44. Advances of small molecule targeting of kinases.
Berndt N; Karim RM; Schönbrunn E
Curr Opin Chem Biol; 2017 Aug; 39():126-132. PubMed ID: 28732278
[TBL] [Abstract][Full Text] [Related]
45. A structural atlas of kinases inhibited by clinically approved drugs.
Wang Q; Zorn JA; Kuriyan J
Methods Enzymol; 2014; 548():23-67. PubMed ID: 25399641
[TBL] [Abstract][Full Text] [Related]
46. A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.
Robak P; Robak T
Curr Med Chem; 2012; 19(31):5294-318. PubMed ID: 22830347
[TBL] [Abstract][Full Text] [Related]
47. Development and strategies of VEGFR-2/KDR inhibitors.
Huang L; Huang Z; Bai Z; Xie R; Sun L; Lin K
Future Med Chem; 2012 Sep; 4(14):1839-52. PubMed ID: 23043480
[TBL] [Abstract][Full Text] [Related]
48. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
Zhang J; Jiang X; Jiang Y; Guo M; Zhang S; Li J; He J; Liu J; Wang J; Ouyang L
Eur J Med Chem; 2016 Jan; 108():495-504. PubMed ID: 26717201
[TBL] [Abstract][Full Text] [Related]
49. Redefining the Protein Kinase Conformational Space with Machine Learning.
Ung PM; Rahman R; Schlessinger A
Cell Chem Biol; 2018 Jul; 25(7):916-924.e2. PubMed ID: 29861272
[TBL] [Abstract][Full Text] [Related]
50. Prospects for pharmacological targeting of pseudokinases.
Kung JE; Jura N
Nat Rev Drug Discov; 2019 Jul; 18(7):501-526. PubMed ID: 30850748
[TBL] [Abstract][Full Text] [Related]
51. Aromatic Rings as Molecular Determinants for the Molecular Recognition of Protein Kinase Inhibitors.
Zhu Y; Alqahtani S; Hu X
Molecules; 2021 Mar; 26(6):. PubMed ID: 33810025
[TBL] [Abstract][Full Text] [Related]
52. Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases.
Zhu Y; Hu X
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296718
[TBL] [Abstract][Full Text] [Related]
53. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.
Zhong L; Li Y; Xiong L; Wang W; Wu M; Yuan T; Yang W; Tian C; Miao Z; Wang T; Yang S
Signal Transduct Target Ther; 2021 May; 6(1):201. PubMed ID: 34054126
[TBL] [Abstract][Full Text] [Related]
54. A small molecule discrimination map of the antibiotic resistance kinome.
Shakya T; Stogios PJ; Waglechner N; Evdokimova E; Ejim L; Blanchard JE; McArthur AG; Savchenko A; Wright GD
Chem Biol; 2011 Dec; 18(12):1591-601. PubMed ID: 22195561
[TBL] [Abstract][Full Text] [Related]
55. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
56. Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients.
Janku F
Cancer Treat Rev; 2017 Sep; 59():93-101. PubMed ID: 28779636
[TBL] [Abstract][Full Text] [Related]
57. Small molecule kinase inhibitors as anti-cancer therapeutics.
Chahrour O; Cairns D; Omran Z
Mini Rev Med Chem; 2012 May; 12(5):399-411. PubMed ID: 22303944
[TBL] [Abstract][Full Text] [Related]
58. Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
Song Z; Ge Y; Wang C; Huang S; Shu X; Liu K; Zhou Y; Ma X
J Med Chem; 2016 Jul; 59(14):6580-94. PubMed ID: 26882288
[TBL] [Abstract][Full Text] [Related]
59. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
Roskoski R
Pharmacol Res; 2013 Feb; 68(1):68-94. PubMed ID: 23201355
[TBL] [Abstract][Full Text] [Related]
60. Identification of new MRP4 inhibitors from a library of FDA approved drugs using a high-throughput bioluminescence screen.
Cheung L; Yu DM; Neiron Z; Failes TW; Arndt GM; Fletcher JI
Biochem Pharmacol; 2015 Feb; 93(3):380-8. PubMed ID: 25462817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
